Business Context and Reporting Period
Company: Microbot Medical Inc. (MBOT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: Microbot is a pre-commercial, clinical-stage medical device company developing the LIBERTY® Endovascular Robotic Surgical System, a fully disposable robotic system for endovascular procedures. The company has not yet generated revenue from operations and relies on capital raises and government grants to fund research and development (R&D).
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,601) | $(2,371) |
| Net Loss Per Share (Basic & Diluted) | $(0.08) | $(0.17) |
| Operating Loss | $(3,021) | $(2,384) |
| Cash and Cash Equivalents | $3,217 | $3,114 (Dec 31, 2024) |
| Marketable Securities | $27,173 | $2,356 (Dec 31, 2024) |
| Total Current Assets | $30,656 | $5,819 (Dec 31, 2024) |
| Total Liabilities | $1,941 | $2,501 (Dec 31, 2024) |
| Shareholders' Equity | $28,951 | $3,530 (Dec 31, 2024) |
| Cash Flow from Operations | $(2,874) | $(2,420) |
| Cash Flow from Financing | $27,806 | $2,397 |
Material Changes vs. Prior Period
- Capital Position: Total assets increased significantly from $6.0 million (Dec 31, 2024) to $30.9 million (Mar 31, 2025), driven by a surge in marketable securities from $2.4 million to $27.2 million following equity raises in January and February 2025.
- Operating Expenses: Operating loss widened by $637,000 year-over-year. R&D expenses increased by $290,000 due to higher payroll and manufacturing costs for the LIBERTY system. General and Administrative (G&A) expenses increased by $347,000 due to higher payroll, professional services, and travel costs.
- Other Income: The company recorded $316,000 in other income in Q1 2025, compared to zero in Q1 2024. This resulted from a favorable appellate court ruling in the "Mona litigation," where the company received a judgment net of legal fees.
- Share Count: Weighted average shares outstanding increased from ~14.1 million in Q1 2024 to ~31.1 million in Q1 2025, reflecting significant equity issuances.
Guidance, Outlook, and Risks
- Regulatory Milestones: The company submitted a 510(k) premarket notification to the FDA in December 2024 and anticipates marketing clearance in Q2 2025. CE Mark approval is anticipated in the second half of 2026.
- Liquidity Outlook: Management believes current funds, combined with recent capital raises, are sufficient to fund operations for more than 12 months. The company expects to continue incurring losses until commercialization.
- Capital Raises: In Q1 2025, the company raised approximately $27.8 million in net proceeds through registered direct offerings, ATM sales, and warrant exercises. Subsequent events in April and May 2025 generated an additional ~$2.6 million from warrant exercises.
- Risk Factors:
- Geopolitical Risk: Ongoing military operations in Israel (where R&D is based) pose risks to supply chains, vendor activity, and flight logistics. While no material adverse effect has been confirmed to date, escalation could impact clinical and regulatory milestones.
- Commercialization Risk: No assurance is given that FDA clearance will be obtained or that the product will be commercially successful.
Investor Verification Checklist
- FDA Clearance Timeline: Verify if the anticipated Q2 2025 FDA marketing clearance is met, as this is the primary catalyst for revenue generation.
- Burn Rate vs. Cash Runway: Monitor quarterly operating cash burn against the $30.4 million in liquid assets (cash + marketable securities) to confirm the >12 month runway assertion.
- Geopolitical Impact: Assess any future disruptions to the Israeli R&D facility or supply chain due to the ongoing conflict.
- Dilution: Review the impact of outstanding preferred investment options (Series G, H, and I) and warrants on future share count and per-share value.
- Government Grants: Confirm the status of Israeli Innovation Authority (IIA) grants and any associated royalty obligations upon future sales.